Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Ongoing health technology assessments by the Swedish SBU

04 Mar 2021

The Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) systematically evaluates healthcare technologies and practices from medical, economic, ethical, and social standpoints. The results from the evaluations are published as systematic literature reviews and are used as an unbiased and scientifically reliable basis for decisions.

Currently, the SBU is working on the following assessments related to medical procedures or technologies:

  • Treatment of rectal diastasis;
  • Treatment and rehabilitation of people with fibromyalgia;
  • Aids for movement and movement for people with permanent mobility impairments;
  • Internet-mediated psychological treatment for anxiety and mood disorders (update);
  • Complex interventions for long-term pain;
  • Methods for diagnosing and treating lipoedema;
  • Screening for spinal muscular atrophy.

The details of the ongoing assessments can be found here.

Health technology assessments of the SBU do not have a direct impact on reimbursement or funding of medical technologies, although they can impact the adoption of evaluated methods. 

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).